Back to Authors

Weihl, Conrad C.

https://orcid.org/0000-0002-3816-6124

Mayo Clinic

Washington University in St. Louis

Citations 4

An ethanol-induced loss of the lipid droplet–associated segregase VCP/p97 leads to hepatic steatosis
Sen, Sandhya , Weller, Shaun G. , Schulze, Ryan J. , Ding, Donglin , Casey, Carol A. , Weihl, Conrad C. , McNiven, Mark A. , Weihl, Conrad , Casey, Carol A , Ding, Donglin

Journal of Cell Biology | May 31, 2025 | Volume: 224 | Issue: 8 | Pages: No page available

10.1083/jcb.202408205 Get It

The liver stores substantial numbers of neutral lipid organelles termed lipid droplets (LDs) that accumulate within hepatocytes in response to chronic ethanol (EtOH) consumption leading to hepatic steatosis. Mass spectrometry analysis of LDs isolated from EtOH-damaged rat livers revealed a substantial reduction in the valosin-containing protein ATPase (VCP/p97) that acts to remove targeted proteins from cellular membranes for degradation. Experimental disruption of VCP function resulted in an increase in LD content in hepatocytes and mouse livers along with a marked increase in LD-associated hydroxysteroid dehydrogenase (HSD17β13) known to contribute to hepatic steatosis. Surprisingly, treatment of hepatocytes with the proteasome inhibitor MG132 had no effect on HSD17β13 levels, while a disruption of lysosome function and chaperone-mediated autophagy increased cellular HSD17β13 levels substantially. These findings provide new insights into the cellular mechanisms by which the liver regulates its lipid stores and how this is disrupted by chronic EtOH exposure.
Expert panel curation of 31 genes in relation to limb girdle muscular dystrophy
McNulty, Shannon , Thaxton, Courtney , Elnagheeb, Marwa , Owens, Emma, Flowers, May , Nunnery, Teagan, Self, Autumn, Palus, Brooke, Gorokhova, Svetlana , Kennedy, April , Niu, Zhiyv , Johari, Mridul , Maīga, Alassane Baneye , Macalalad, Kelly, Clause, Amanda , Beckmann, J. , Bronicki, Lucas, Ganesh, Vijay S , Kang, Peter B. , Kesari, Akanchha, Lek, Monkol , Lévy, Jennifer, Rufibach, Laura , Savarese, Marco , Spencer, Melissa J. , Tasca, Giorgio , Weihl, Conrad C. , Gorokhova, Svetlana , Niu, Zhiyv , Clause, Amanda R , Kang, Peter B , Savarese, Marco , Tasca, Giorgio , Thaxton, Courtney , Mohan, Shruthi , Cooper, Sandra T. , Straub, Volker

Annals of Clinical and Translational Neurology | August 31, 2024 | Volume: 11 | Issue: 9 | Pages: 2268-2276

10.1002/acn3.52127 Get It

Abstract Objective Limb girdle muscular dystrophies (LGMDs) are a group of genetically heterogeneous autosomal conditions with some degree of phenotypic homogeneity. LGMD is defined as having onset >2 years of age with progressive proximal weakness, elevated serum creatine kinase levels and dystrophic features on muscle biopsy. Advances in massively parallel sequencing have led to a surge in genes linked to LGMD. Methods The ClinGen Muscular Dystrophies and Myopathies gene curation expert panel (MDM GCEP, formerly Limb Girdle Muscular Dystrophy GCEP) convened to evaluate the strength of evidence supporting gene–disease relationships (GDR) using the ClinGen gene–disease clinical validity framework to evaluate 31 genes implicated in LGMD. Results The GDR was exclusively LGMD for 17 genes, whereas an additional 14 genes were related to a broader phenotype encompassing congenital weakness. Four genes ( CAPN3 , COL6A1 , COL6A2 , and COL6A3 ) were split into two separate disease entities, based on each displaying both dominant and recessive inheritance patterns, resulting in curation of 35 GDRs. Of these, 30 (86%) were classified as definitive, 4 (11%) as moderate, and 1 (3%) as limited. Two genes, POMGNT1 and DAG1 , though definitively related to myopathy, currently have insufficient evidence to support a relationship specifically with LGMD. Interpretation The expert‐reviewed assertions on the clinical validity of genes implicated in LGMDs form an invaluable resource for clinicians and molecular geneticists. We encourage the global neuromuscular community to publish case‐level data that help clarify disputed or novel LGMD associations.
Provisional practice recommendation for the management of myopathy in VCP‐associated multisystem proteinopathy
Roy, Bhaskar , Peck, Allison , Evangelista, Teresinha , Díaz‐Manera, Jordi , Korb, Manisha Kak , Wicklund, Matthew , Milone, Margherita , Freimer, Miriam , Kushlaf, Hani , Villar‐Quiles, Rocío‐Nur , Stojkovic, Tanya , Needham, Merrilee , Palmio, Johanna , Keung, Benison , Mozaffar, Tahseen , Weihl, Conrad C. , Kimonis, Virginia , Milone, M , Díaz-Manera, Jordi , Pfeffer, Gerald , Wang, Leo L. , Lloyd, Thomas E , Roy, Bhaskar

Annals of Clinical and Translational Neurology | April 7, 2023 | Volume: 10 | Issue: 5 | Pages: 686-695

10.1002/acn3.51760 Get It

AbstractValosin‐containing protein (VCP)‐associated multisystem proteinopathy (MSP) is a rare genetic disorder with abnormalities in the autophagy pathway leading to various combinations of myopathy, bone diseases, and neurodegeneration. Ninety percent of patients with VCP‐associated MSP have myopathy, but there is no consensus‐based guideline. The goal of this working group was to develop a best practice set of provisional recommendations for VCP myopathy which can be easily implemented across the globe. As an initiative by Cure VCP Disease Inc., a patient advocacy organization, an online survey was initially conducted to identify the practice gaps in VCP myopathy. All prior published literature on VCP myopathy was reviewed to better understand the different aspects of management of VCP myopathy, and several working group sessions were conducted involving international experts to develop this provisional recommendation. VCP myopathy has a heterogeneous clinical phenotype and should be considered in patients with limb‐girdle muscular dystrophy phenotype, or any myopathy with an autosomal dominant pattern of inheritance. Genetic testing is the only definitive way to diagnose VCP myopathy, and single‐variant testing in the case of a known familial VCP variant, or multi‐gene panel sequencing in undifferentiated cases can be considered. Muscle biopsy is important in cases of diagnostic uncertainty or lack of a definitive pathogenic genetic variant since rimmed vacuoles (present in ~40% cases) are considered a hallmark of VCP myopathy. Electrodiagnostic studies and magnetic resonance imaging can also help rule out disease mimics. Standardized management of VCP myopathy will optimize patient care and help future research initiatives.